BTBD9 antibody (AA 200-400)

Catalog No. ABIN7871998

The Mouse Monoclonal anti-BTBD9 antibody (Clone BTBD9-7501) (ABIN7871998) specifically detects BTBD9 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for BTBD9 antibody (AA 200-400) (ABIN7871998)

Target: BTBD9 (BTB (POZ) Domain Containing 9 (BTBD9))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This BTBD9 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: BTBD9-7501

Product Details anti-BTBD9 Antibody

Binding Specificity: AA 200-400

Purpose: BTBD9 Antibody / BTB/POZ domain-containing protein 9 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A recombinant partial protein sequence (within amino acids 200-400) from the human protein was used as the immunogen for the BTBD9 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the BTBD9 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the BTBD9 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for BTBD9

Target: BTBD9 (BTB (POZ) Domain Containing 9 (BTBD9))

Alternative Name: BTBD9

Background: BTBD9 (BTB/POZ domain-containing protein 9) is a 612 amino acid protein that contains one BTB/POZ domain and one BACK (BTB/Kelch associated) domain. The BTB/POZ domain mediates homomeric and heteromeric POZPOZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including Bcl-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. This suggests that BTBD9 may play a role in transcription regulation. Genetic variations in the gene that encodes BTBD9 have been associated with susceptibility to restless legs syndrome type 6 (RLS6), a condition characterized by an uncontrollable urge to move the legs while resting.

UniProt: Q96Q07

Pathways: Transition Metal Ion Homeostasis